Medicine
Ogivri kit
Ogivri kit is a prescription medicine containing Trastuzumab, marketed by Mylan Institutional, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store Ogivri vials in the refrigerator at 2° to 8°C (36° to 46°F) until time…
Key facts
- Active ingredient (INN)
- Trastuzumab
- Brand
- Ogivri
- Dosage form
- Kit
- Packs
- 1 kit
- Marketing authorisation holder
- Mylan Institutional
- Manufacturers
- Mylan InstitutionalBiocon BiologicsIndia
- Origin register
- US FDA, United States
- Storage
- Store Ogivri vials in the refrigerator at 2° to 8°C (36° to 46°F) until time of reconstitution.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FD01 Trastuzumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 November 2019
- Identifiers
- RxCUI 2179753, 2179758, 2179760 +1DailyMed set ID b6465b44-a6dd-f99c-d009-6851cf05169cNDC 83257-004, 67457-847Application BLA761074
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * 20 mL in 1 vial, multi-dose * 20 mL in 1 vial | 67457-847-44 | Mylan Institutional | 29 November 2019 |
| 1 kit in 1 carton * 20 mL in 1 vial, multi-dose * 20 mL in 1 vial | 83257-004-12 | Biocon BiologicsIndia | 1 October 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Trastuzumab kit.
Other strengths and forms of Trastuzumab
Clinical summary
Trastuzumab is an HER2/neu receptor antagonist indicated in adults for the treatment of HER2-overexpressing breast cancer, among other approved uses. It is available as powder for injection and kits for intravenous use. MedsAcross supplies Trastuzumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TrastuzumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Herceptin prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
- Herceptin: European public assessment report (EPAR) · European Medicines Agency
- Tuznue: European public assessment report (EPAR) · European Medicines Agency
Need Ogivri kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.